Chief Medical Officer David Malcom Rodman of Mineralys Therapeutics (NASDAQ:MLYS) completed a series of equity transactions in mid-April 2026, selling a total of 20,406 shares of the company's common stock on April 13 and April 15 for aggregate proceeds of approximately $548,672. The sales were executed at per-share prices that ranged from $26.5391 to $27.66.
On April 13, Rodman also exercised stock options to acquire 14,058 shares of Mineralys common stock, exercising those options at strike prices between $1.08 and $14.25 for a combined outlay of $102,365. The option exercise and the subsequent sales were carried out under a pre-established Rule 10b5-1 trading plan that the officer adopted on October 6, 2025.
Following the completion of these transactions, Rodman directly holds 69,792 shares of Mineralys Therapeutics. At the time of reporting, the company's share price stood at $30.42, representing a 125% increase over the last 12 months. An InvestingPro analysis referenced alongside the disclosure values Mineralys at a Fair Value of $31.6, suggesting the stock may still be trading below that estimate.
The company released fourth-quarter 2025 financial results that included an earnings-per-share figure of -0.4, which outperformed expectations that had called for -0.94. Management discussed the quarter on the company’s earnings call, where the EPS beat was presented despite noted increases in general and administrative expenses and recent trial outcomes.
Analyst responses to Mineralys’ developments have varied. BofA Securities raised its price target to $51.00 and kept a Buy rating, citing progress in the clinical development of lorundrostat for uncontrolled hypertension. Stifel maintained a Buy rating as well, with a $52.00 target and commentary that emphasized the company’s preparations for a potential commercial launch of lorundrostat. In contrast, Jefferies reduced its price target to $30 from $42 and left a Hold rating in place, pointing to uncertainties surrounding the strategic approach for lorundrostat.
In personnel news, Mineralys named Jeffrey A. Munsie as Chief Legal Officer. The appointment was noted alongside other corporate updates tied to the company’s commercialization and strategic planning activities.
InvestingPro content accompanying the transaction disclosure indicates that subscribers can access seven additional exclusive tips about MLYS and full Pro Research Reports covering this company along with more than 1,400 other U.S. equities.
This report summarizes filings and disclosures related to insider transactions, recent financial results and analyst coverage as provided in company and market disclosures. It does not speculate beyond the information released in those disclosures.